Immunity against soft-tissue sarcomas

Current Oncology Reports

Volumn 5, Issue 4, 2003, Pages 282-287

  Maki, Robert G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CANCER VACCINE; CHAPERONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOLIPID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 96; RECOMBINANT INTERLEUKIN 2; TELOMERASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANEMIA; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG ERUPTION; DRUG SYNTHESIS; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; MEDICAL TECHNOLOGY; MOLECULAR BIOLOGY; NAUSEA AND VOMITING; NONHUMAN; NOSE CONGESTION; REVIEW; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; TUMOR IMMUNITY; CONTROLLED CLINICAL TRIAL; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METHODOLOGY; MORTALITY; PHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SARCOMA; SENSITIVITY AND SPECIFICITY; SOFT TISSUE TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIGENS, NEOPLASM; CANCER VACCINES; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SARCOMA; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037658620     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0067-x     Document Type: Review

References (37)

1. Jemal A, Murray T, Samuels A, et al.: Cancer statistics, 2003. CA Cancer J Clin 2003, 53:5-26.
2. Wunder JS, Healey JH, Davis AM, Brennan MF: A comparison of staging systems for localized extremity soft tissue sarcoma. Cancer 2000, 88:2721-2730.
3. Gill J, Bourboulia D, Wilkinson J, et al.: Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002, 31:384-390.
4. Wilkinson J, Cope A, Gill J, et al.: Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 2002, 76:2634-2640.
5. Green WR: Cytotoxic T lymphocytes to endogenous mouse retroviruses and mechanisms of retroviral escape. Immunol Rev 1999, 168:271-286.
6. Reitamo JJ: The desmoid tumor. IV. Choice of treatment, results, and complications. Arch Surg 1983, 118:1318-1322.
7. Scanlan MJ, Chen YT, Williamson B, et al.: Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998, 76:652-658.
8. Tureci O, Chen YT, Sahin U, et al.: Expression of SSX genes in human tumors. Int J Cancer 1998, 77:19-23.
9. van der Bruggen P, Traversari C, Chomez P, et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
10. Knuth A, Wolfel T, Meyer zum Buschenfelde KH: T cell responses to human malignant tumours. Cancer Surv 1992, 13:39-52.
11. Schultze JL, Maecker B, von Bergwelt-Baildon MS, et al.: Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens. Vox Sang 2001, 80:81-89.
12. Chang HR, Cordon-Cardo C, Houghton AN, et al.: Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer 1992, 70:633-638.
13. Perez CA, Ravindranath MH, Soh D, et al.: Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J 2002, 8:384-394.
14. Antonescu CR, Busam KJ, Iversen K, et al.: MAGE antigen expression in monophasic and biphasic synovial sarcoma. Hum Pathol 2002, 33:225-229.
15. Jungbluth AA, Antonescu CR, Busam KJ, et al.: Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 2001, 94:252-256.
16. Scanlan MJ, Gordon CM, Williamson B, et al.: Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer 2002, 98:485-492.
17. Nielsen TO, West RB, Linn SC, et al.: Molecular characterization of soft tissue tumors: a gene expression study. Lancet 2002, 359:1301-1307.
18. Allander SV, Illei PB, Chen Y, et al.: Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002, 161:1587-1595.
19. Belz GT, Xie W, Altman JD, Doherty PC: A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge. J Virol 2000, 74:3486-3493.
20. Jager E, Nagata Y, Gnjatic S, et al.: Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A 2000, 97:4760-4765.
21. Sato Y, Nabeta Y, Tsukahara T, et al.: Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol 2002, 169:1611-1618.
22. Worley BS, van den Broeke LT, Goletz TJ, et al.: Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res 2001, 61:6868-6875.
23. Albert ML, Pearce SF, Francisco LM, et al.: Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998, 188:1359-1368.
24. Steinman RM, Pope M: Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002, 109:1519-1526.
25. Dagher R, Long LM, Read EJ, et al.: Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 2002, 38:158-164.
26. Matsuzaki A, Suminoe A, Hattori H, et al.: Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J Pediatr Hematol Oncol 2002, 24:220-223.
27. Geiger J, Hutchinson R, Hohenkirk L, et al.: Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 2000, 356:1163-1165.
28. Mahvi DM, Shi FS, Yang NS, et al.: Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study. Hum Gene Ther 2002, 13:1711-1721.
29. Dranoff G, Jaffee E, Lazenby A, et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993, 90:3539-3543.
30. Simons JW, Jaffee EM, Weber CE, et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997, 57:1537-1546.
31. Belli F, Testori A, Rivoltini L, et al.: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002, 20:4169-4180.
32. Vonderheide RH: Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002, 21:674-679.
33. Disis ML, Gooley TA, Rinn K, et al.: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002, 20:2624-2632.
34. Moody DB, Guy MR, Grant E, et al.: CD1b-mediated T cell recognition of a glycolipid antigen generated from mycobacterial lipid and host carbohydrate during infection. J Exp Med 2000, 192:965-976.
35. O'Neill LA: Wanted: a molecular basis for specificity in toll-like receptor signal transduction. Mol Cell 2002, 10:969-971.
36. Dutoit V, Taub RN, Papadopoulos KP, et al.: Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 2002, 110:1813-1822.
37. Celis E: Getting peptide vaccines to work: just a matter of quality control? J Clin Invest 2002, 110:1765-1768.